Services
Equity Trading with CA Abhay
Option Trading with CA Abhay
Equity Investment with CA Abhay
FNO Stocks with CA Abhay
Stock Market Masterclass
Hamps Bio IPO Makes Strong Debut with 90% Listing Premium on BSE SME
Team Finance Saathi
20/Dec/2024
What's covered under the Article:
- Strong debut of Hamps Bio IPO with 90% premium on BSE SME.
- Company’s focus on pharmaceutical formulations and freeze-dried food products.
- Financials, subscription status, and GMP trends indicating positive investor outlook.
Hamps Bio made a strong debut on the BSE SME platform on December 20, 2024, with its shares listing at ₹96.9, a significant 90% premium over the IPO price of ₹51. This promising start reflects investor confidence in the company, which is engaged in the ethical marketing and distribution of pharmaceutical products, including tablets, syrups, capsules, and injectables, alongside its freeze-dried and frozen food products.
The IPO raised ₹6.22 crore through a fixed price issue, with 12.20 lakh shares offered for subscription. The subscription period for the IPO ran from December 13 to 17, 2024, and the issue was oversubscribed by 1003.34 times by its final day, signaling high demand from investors. The price band for the IPO was set at ₹51 per equity share, with a market capitalization at the IPO price of ₹22.21 crore.
The company’s diverse product range includes pharmaceutical formulations and nutrition supplements, marketed under the brand "Hamps", as well as freeze-dried and frozen products in the FMCG sector. The company’s growth trajectory is supported by strong promoters, including Herrik Shah and Shrenik Shah, with a focus on expanding its market reach.
Hamps Bio’s revenues from operations for FY2024 stood at ₹436.42 lakh, showing steady growth from previous years. The company’s EBITDA for FY2024 was ₹75.11 lakh, and its Profit After Tax (PAT) reached ₹34.08 lakh, reflecting positive financial performance.